Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced it has signed contracts with providers for production of their BioLexa therapeutic, in preparation for upcoming toxicology and clinical studies.
Hoth has begun preparations for the testing of its formulation for both active and vehicle stability. The Company has engaged the services of both Particle Sciences, Inc. and Regis Technologies, Inc., in order to fulfill the necessary formulation and production of both Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) of its biopharmaceutical. The BioLexa Platform is a proprietary, patented antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis.
“Management is extremely pleased to announce this significant step in our developmental track,” stated Robb Knie, CEO of Hoth Therapeutics. “Atopic dermatitis often has a negative impact on patients’ overall health and quality of life. Current treatments, such as topical corticosteroids and other treatments frequently carry harsh side effects. Hoth looks forward to initiating these clinical trials, as we believe that our BioLexa therapeutic has the potential to become a much needed treatment for this underserved market.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.